Brief: Argent Biopharma Enters Global Licensing Transaction
07/07/2026 02:28
BRIEF-Argent Biopharma Enters Global Licensing Transaction July 7 (Reuters) - Argent BioPharma Ltd RGT.AX:
ENTERS A GLOBAL LICENSING TRANSACTION FOR CANNEPIL WITH SPLASH BEVERAGE GROUP INC
TRANSACTION INCLUDES $5.5 MILLION UPFRONT CONSIDERATION FOR GLOBAL LICENSING RIGHTS
TO RECEIVE A 15% NET REVENUE ROYALTY ON FUTURE SBEV GLOBAL CANNEPIL REVENUES
Further company coverage: RGT.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Executes Global Licence For Non-Core Cannabis Genetics
Brief: Argent Biopharma Files Provisional US Patent On Immune Modulation And Longevity
Australia's Argent BioPharma rises to over 1-month high on new licence agreement
Brief: Argent Biopharma Signs NLC Licence To Expand Antiviral Portfolio
Brief: Argent Biopharma Says FDA-CVM Established Inad File For Cannepil Veterinary Program